ORCID Profile
0000-0003-0618-1298
Current Organisation
James Cook University
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Elsevier BV
Date: 05-2019
DOI: 10.1016/J.ANIREPROSCI.2019.03.003
Abstract: Concentrations of progesterone before AI have had variable effects on fertility in both Bos indicus and Bos taurus cattle. The aim of this study was to determine if fertility and concentrations of progesterone after AI were affected in Bos indicus females when pre-ovulatory follicles develop in the absence or presence of a corpus luteum (CL). Between 6.5-7.5 days after a synchronised oestrus, all follicles ≥4 mm in diameter were aspirated (Day 0) and cloprostenol was administered on Days 0 and 1 (LP4, n = 36) or on Days 4 and 5 (HP4, n = 40). Animals were inseminated on detection of oestrus until Day 9. Breeding continued using natural mating between Days 9 and 19, AI on detection of oestrus between Day 19 and 29 and natural mating between Days 29-90. Mean concentrations of progesterone were less on Days 2-4 in the LP4 compared to the HP4-treated animals but similar on Days 14 and 20. In the LP4- compared to the HP4-treated animals, the odds of being detected in oestrus and ovulating close to the first AI were similar, but odds of pregnancy to first AI (OR = 0.19, 95% CI 0.07 - 0.52) and after 1, 4 and 13 weeks of breeding were less (P ≤ 0.051). Absence of a CL and relatively lesser concentrations of progesterone during emergence of pre-ovulatory follicles resulted in lesser pregnancy rates to AI in Bos indicus cattle but did not affect concentrations of P4 after ovulation.
Publisher: Elsevier BV
Date: 08-2015
DOI: 10.1016/J.ANIREPROSCI.2015.06.012
Abstract: The aim of this study was to determine the effects in Bos indicus calves of intra-testicular injection of either saline (n=9) or one of two doses of zinc acetate ((ZA1, 57.75mg, n=10, or ZA2, 71.75mg, n=10) or surgical castration (n=9) on circulating concentrations of testostosterone and liveweight. Human chorionic gonadotrophin (hCG, 1500IU) was administered 202 and 525 days after treatment on Day 0 and animals were slaughtered on Day 860. In animals left intact treatment with ZA reduced mean serum concentrations of testosterone (Saline: 5.58±0.79ng/mL, ZA1: 1.28±0.27ng/mL, ZA2: 1.01±0.17ng/mL P<0.001) and concentrations 48h following administration of hCG. The maximum concentration of testosterone recorded throughout the study in six out of 19 animals treated with ZA was ≤0.21ng/mL. Treatment with ZA did not significantly affect live weights or carcass weights or result in any detectable scrotal lesions. Animals with concentrations of testosterone ≥1.0ng/mL exhibited greater liveweights throughout most of the study and yielded heavier carcass weights (340.9±7.02 versus 309.3±6.17kg, P=0.002). It is concluded that a single, intra-testicular administration of either 57.75mg or 71.75mg of ZA was able to similarly reduce circulating concentrations of testosterone without significantly affecting liveweights or carcass weights. Treatment with ZA can result in variation in circulating concentrations of testosterone which could lead to differences in behaviour, liveweights and carcass characteristics.
Publisher: Wiley
Date: 28-06-2022
DOI: 10.1111/AVJ.13196
Abstract: This study investigated the effects of administering saline, 100 or 250 μg of gonadotrophin releasing hormone (GnRH) on ovarian response, synchrony of oestrus and ovulation and chronic stress response in Bos indicus cattle. Randomised control. Animals were either left untreated (n = 20) or on day 0 treated with an intravaginal progesterone releasing device and either saline (n = 24), 100 μg (n = 35), or 250 (n = 35) μg of GnRH, intramuscular (IM). Blood was s led 1.4 h after administration of treatment to monitor concentrations of luteinising hormone (LH) and P4 in serum and again 5 days later. On day 5 intravaginal P4 releasing device were removed, cloprostenol was administered IM and again 8 h later. Oestrus and ovulation were then monitored with ultrasonography for 6.5 days. Hair was clipped on day 55 for analysis of hair cortisol concentrations (HCC). No significant differences were found between Saline and GnRH treatments in the odds of inducing a new corpus luteum (CL) and the synchrony of oestrus or ovulation. HCC did not differ significantly between treatments. Mean concentrations of LH in serum on day 0 were less in the Saline compared to 100 and 250 μg GnRH treatments but did not differ between different doses of GnRH. Mean concentrations of LH and the odds of inducing a new CL were not increased after administering 250 μg compared to 100 μg of GnRH. Animal handling events in the study did not influence HCC. Further research is needed to better optimise responses to GnRH in B . indicus cattle.
Publisher: MDPI AG
Date: 29-03-2019
DOI: 10.3390/NU11040743
Abstract: Omega-3 polyunsaturated fatty acids (n-3 PUFA) are termed essential fatty acids because they cannot be synthesized de novo by humans due to the lack of delta-12 and delta-15 desaturase enzymes and must therefore be acquired from the diet. n-3 PUFA include α-linolenic acid (ALA, 18:3n-3), eicosapentaenoic (EPA, 20:5n-3), docosahexaenoic (DHA, 22:6n-3), and the less recognized docosapentaenoic acid (DPA, 22:5n-3). The three long-chain (≥C20) n-3 PUFA (n-3 LC-PUFA), EPA, DHA, and DPA play an important role in human health by reducing the risk of chronic diseases. Up to the present time, seafood, and in particular, fish oil-derived products, have been the richest sources of n-3 LC-PUFA. The human diet generally contains insufficient amounts of these essential FA due largely to the low consumption of seafood. This issue provides opportunities to enrich the content of n-3 PUFA in other common food groups. Milk and milk products have traditionally been a major component of human diets, but are also among some of the poorest sources of n-3 PUFA. Consideration of the high consumption of milk and its processed products worldwide and the human health benefits has led to a large number of studies targeting the enhancement of n-3 PUFA content in dairy products. The main objective of this review was to evaluate the major strategies that have been employed to enhance n-3 PUFA content in dairy products and to unravel potential knowledge gaps for further research on this topic. Nutritional manipulation to date has been the main approach for altering milk fatty acids (FA) in ruminants. However, the main challenge is ruminal biohydrogenation in which dietary PUFA are hydrogenated into monounsaturated FA and/or ultimately, saturated FA, due to rumen microbial activities. The inclusion of oil seed and vegetable oil in dairy animal diets significantly elevates ALA content, while the addition of rumen-protected marine-derived supplements is the most effective way to increase the concentration of EPA, DHA, and DPA in dairy products. In our view, the mechanisms of n-3 LC-PUFA biosynthesis pathway from ALA and the biohydrogenation of in idual n-3 LC-PUFA in ruminants need to be better elucidated. Identified knowledge gaps regarding the activities of candidate genes regulating the concentrations of n-3 PUFA and the responses of ruminants to specific lipid supplementation regimes are also critical to a greater understanding of nutrition-genetics interactions driving lipid metabolism.
Publisher: Wiley
Date: 02-02-2022
DOI: 10.1111/AVJ.13142
Abstract: To investigate if modification of a gonadotrophin‐releasing hormone (GnRH) based protocol to synchronise oestrus in Bos indicus cattle will improve response rates to the first administration of GnRH and improve pregnancy rates to artificial insemination (AI). Randomised control study. Bos indicus heifers, nonlactating and lactating cows allocated to a GnRH‐18 treatment (n = 237) were treated with an intravaginal device (IVD) and cloprostenol (0.5 mg IM) on day −11 and on day 0 remaining animals in the GnRH‐7 treatment (n = 222) were administered an IVD and every animal was treated with GnRH (100 μg IM). On day 7, equine chorionic gonadotrophin (400 IU IM) and cloprostenol were administered and IVD's were removed. Animals detected in oestrus on day 9 were artificially inseminated while those not detected in oestrus were administered GnRH (100 μg IM) at 1700 hours and inseminated on day 10. Bulls were inserted 2 weeks after completion of AI and remained until day 65. The GnRH‐18 protocol increased the diameter of the largest follicle in the ovary on day 0, increased the percentage of new CL's induced after day 0 (46.3% vs 36.1%, for GnRH‐18 and GnRH‐7 P = 0.022), decreased circulating concentrations of progesterone on day 7 and increased odds of pregnancy to AI in heifers but not in nonlactating and lactating cows. Treatment with the GnRH‐18 compared to the GnRH‐7 protocol increased pregnancy rates to AI in heifers but not in nonlactating or lactating cows.
Publisher: Wiley
Date: 18-01-2021
DOI: 10.1111/AVJ.13055
Publisher: Wiley
Date: 16-04-2023
DOI: 10.1111/AVJ.13244
Abstract: There is a need for a safe, effective and practical method of oestrus suppression in the mare. The aim of this study was to monitor ovarian activity in mares exposed to either 9.4 or 28.2 mg deslorelin acetate, a GnRH agonist, in the form of a sustained‐release implant. Following oestrus synchronisation, mares were randomly assigned to one of three groups ( n = 4 per group) and administered either one (Des1 group 9.4 mg) or three (Des3 group 28.2 mg) implants of deslorelin acetate (Suprelorin‐12, Virbac Australia) or one blank implant (Control group Virbac Australia). Mares underwent weekly blood s ling for 12 weeks following implant placement (Day 0–Day 84), with transrectal palpation and ultrasonography of the reproductive tract at all s ling timepoints except Days 56, 70 and 77. All mares showed baseline serum progesterone concentrations (SPC ≤1.3 nmol/L or 0.4 ng/ml) on Day 0. Cycling Control mares showed typical oestrous cyclicity characterised by peaks and troughs in SPC over time. Four of eight treated mares demonstrated a sustained elevation in SPC after the initial ovulation after implant placement SPC declined to baseline levels (Des1 group 2 mares) or remained elevated (Des3 group 2 mares) at the final s ling timepoint on Day 84. Oestrous cyclicity was erratic in three of the remaining four treated mares. In total, 87.5% (7 of 8) of treated mares showed atypical oestrous cyclicity after implant placement. These results suggest that deslorelin acetate disrupts oestrous cyclicity in the mare, which warrants further research.
Publisher: Informa UK Limited
Date: 30-10-0011
Publisher: Elsevier BV
Date: 05-2015
DOI: 10.1016/J.ANIREPROSCI.2015.02.004
Abstract: The aim of this study was to determine the effects in Bos indicus bull calves of intratesticular administration of 1mL of either saline (n=9) or one of the two doses of zinc acetate (ZA1, 57.75mg, n=10 or ZA2, 71.75mg, n=10) on semen quality and testicular changes. Semen was collected by electroejaculation on Days 343, 524 and 783 and animals were slaughtered on Day 860. Treatment reduced median maximum number of progressively motile and morphologically normal sperm collected (P=0.001) and the percentage of animals in which sperm were recovered (saline: 100%, 9/9 ZA1: 44.9%, 4/9 and ZA2: 40.0%, 4/10 P=0.013). Compared to saline treated controls, treatment with ZA reduced the mean diameter of the testes after Day 34 of treatment (treatment×time, P=0.013) and total testicular weight at slaughter (treatment: mean±SEM saline: 569.4±59.0g, ZA1: 249.3±72.9g, ZA2: 247.5±68.1g P=0.004). Histological changes in testes of bulls treated with ZA were characterized by germ cell depletion, vacuolation of Sertoli cells, interstitial fibrosis, epididymal duct atrophy with variable remnants of testicular tissue and degeneration. We conclude that intratesticular administration of two doses of ZA in B. indicus calves is able to severely impair spermatogenesis and cause varying degrees of testicular degeneration and a reduction in testicular diameter and mass. Further investigation is required to determine ways of obtaining more consistent results from treatment.
No related grants have been discovered for John Cavalieri.